Related Experiment Video
Updated: Jul 21, 2026
09:01
The Double-H Maze: A Robust Behavioral Test for Learning and Memory in Rodents
Published on: July 8, 2015
Memory disorders: novel treatments, clinical perspective
1Department of Preclinical and Clinical Pharmacology, University of Florence, Italy.
Life Sciences
|January 1, 1994
Summary
Developing drugs for age-related memory disorders faces challenges. Preclinical tests show promise for cognition enhancers, but clinical efficacy is limited, highlighting the need for novel therapeutic strategies.
Area of Science:
- Neuroscience
- Pharmacology
- Gerontology
Background:
- Societal aging increases demand for treatments targeting age-related memory decline.
- Numerous preclinical studies identify potential cognition enhancers.
- A significant gap exists between preclinical findings and clinical efficacy.
Purpose of the Study:
- To examine the discrepancy between preclinical cognition enhancer results and limited clinical efficacy.
- To discuss the predictivity of preclinical tests for therapeutic efficacy.
- To analyze novel and investigational treatments for memory disorders.
Main Methods:
- Review of preclinical test predictivity.
- Examination of criteria for evaluating therapeutic efficacy.
- Analysis of current and emerging treatments for cognitive enhancement.
Main Results:
- Many identified cognition enhancers show limited success in clinical trials.
- Preclinical test predictivity for clinical outcomes is questionable.
- Tacrine trials suggest limited improvement from solely restoring signal transmission.
Conclusions:
- Restoring disrupted signal transmission alone is insufficient for treating dementia.
- Addressing underlying morphological alterations is crucial for effective memory disorder treatments.
- Future drug development must consider both biochemical and structural changes in the brain.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Role of Neurotransmitters in Memory
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
01:18False Memories
False memories represent a cognitive distortion in which individuals recall events that did not happen, or remember them in an altered form. This phenomenon highlights the brain's constructive nature in processing and recalling memories, emphasizing that memory is not a perfect representation of past events but rather a dynamic reconstruction influenced by various factors.
One primary source of false memories is misattribution, where individuals incorrectly associate external information with...
One primary source of false memories is misattribution, where individuals incorrectly associate external information with...
01:24Treatment Strategies for Psychological Disorders
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...